No Data
No Data
Innovative Capabilities and Promising Data Drive Buy Rating for Nurix Therapeutics
Express News | Needham Reiterates Buy on Nurix Therapeutics, Maintains $27 Price Target
Nurix Therapeutics Analyst Ratings
Nurix Therapeutics Presents Data at AACR 2025 Highlighting Transformative Potential of Proprietary DEL-AI Platform Leveraging Machine Learning To Speed Discovery Of Novel Drugs
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting From Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs